Skip to main content

Advertisement

SpringerLink
Log in

Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

An oxaliplatin-based regimen as the adjuvant treatment for stage III colon cancer demonstrated a survival advantage over fluorouracil (FU) and leucovorin (LV) in the MOSAIC and NSABP C-07 trials. For adjuvant treatment after the resection of metastases from colorectal cancer), active chemotherapy regimens such as FOLFOX are recommended. However, the safety data of FOLFOX are insufficient for its use after metastasectomy of colorectal cancer in Japanese patients. The aim of this study was to evaluate the safety of mFOLFOX6 for adjuvant treatment after the resection of metastases from colorectal cancer.

Methods

Among 67 consecutive patients who received mFOLFOX6 as the adjuvant treatment after resection of metastases from colorectal cancer between September 2002 and March 2009 in our institution, 51 patients who had not received preoperative chemotherapy were reviewed. The mFOLFOX6 treatment comprised oxaliplatin 85 mg/m2 and l-leucovorin 200 mg/m2 given intravenously over a 2-h period on day 1, followed by a 5-FU bolus of 400 mg/m2 and a 46-h infusion of 5-FU 2400 mg/m2, every 2 weeks for up to 12 cycles.

Results

National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTC) grade 3–4 toxicities per patient were: peripheral neuropathy 8%, allergic reaction 4%, aspartate transaminase (AST) 4%, febrile neutropenia 4%, nausea 2%, anorexia 2%, fatigue 2%, alanine transaminase (ALT) 2%, bilirubin 2%, neutrophils 49%, leukocytes 6%, and hemoglobin 2%; 71% of the patients completed the scheduled 12 cycles.

Conclusion

Adjuvant therapy with mFOLFOX6 after resection of metastases from colorectal cancer is feasible for Japanese patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300

    Article  PubMed  Google Scholar 

  2. Koyama Y, Kotake K et al (1997) Overview of colorectal cancer in Japan: report from the Registry of the Japanese Society for Cancer of the Colon and Rectum. Dis Colon Rectum 40(10 Suppl):S2–S9

    Article  PubMed  CAS  Google Scholar 

  3. Kotake K, Honjo S, Sugihara K et al (2003) Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 46(10 Suppl):S32–S43

    PubMed  Google Scholar 

  4. Gunderson LL, Jessup JM, Sargent DJ et al (2010) Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28(2):264–271

    Article  PubMed  Google Scholar 

  5. O’Connell MJ, Mailliard JA, Kahn MJ et al (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15(1):246–250

    PubMed  Google Scholar 

  6. Wolmark N, Rockette H, Mamounas E et al (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17(11):3553–3559

    PubMed  CAS  Google Scholar 

  7. Andre T, Colin P, Louvet C et al (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol 21(15):2896–2903

    Article  PubMed  CAS  Google Scholar 

  8. André T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351

    Article  PubMed  Google Scholar 

  9. André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116

    Article  PubMed  Google Scholar 

  10. Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25(16):2198–2204

    Article  PubMed  CAS  Google Scholar 

  11. Taylor I (1996) Liver metastases from colorectal cancer: lessons from past and present clinical studies. Br J Surg 83(4):456–460

    Article  PubMed  CAS  Google Scholar 

  12. Galandiuk S, Wieand HS, Moertel CG et al (1992) Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 174(1):27–32

    PubMed  CAS  Google Scholar 

  13. Rodgers MS, McCall JL et al (2000) Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg 87(9):1142–1155

    Article  PubMed  CAS  Google Scholar 

  14. Brown RE, Bower MR, Martin RC et al (2010) Hepatic resection for colorectal liver metastases. Surg Clin N Am 90(4):839–852

    Article  PubMed  Google Scholar 

  15. Regnard JF, Grunenwald D, Spaggiari L et al (1998) Surgical treatment for hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66:214–218

    Article  PubMed  CAS  Google Scholar 

  16. Goya T, Miyazawa N, Kondo H et al (1989) Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 64(7):1418–1421

    Article  PubMed  CAS  Google Scholar 

  17. McCormack PM, Burt ME, Bains MS et al (1992) Lung resection of colorectal metastases. 10 year results. Arch Surg 127(12):1403–1406

    Article  PubMed  CAS  Google Scholar 

  18. Ike H, Shimada H, Ohki S et al (2002) Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum 45(4):468–473 (discussion 473-5)

    Article  PubMed  Google Scholar 

  19. Okumura S, Kondo H, Tsuboi M et al (1996) Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 112(4):867–874

    Article  PubMed  CAS  Google Scholar 

  20. Koga R, Yamamoto J, Saiura A et al (2006) Surgical resection of pulmonary metastases from colorectal cancer: four favourable prognostic factors. Jpn J Clin Oncol 36(10):643–648

    Article  PubMed  Google Scholar 

  21. Iizasa T, Suzuki M, Yoshida S et al (2006) Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 82(1):254–260

    Article  PubMed  Google Scholar 

  22. Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24(31):4976–4982

    Article  PubMed  CAS  Google Scholar 

  23. Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26(30):4906–4911

    Article  PubMed  CAS  Google Scholar 

  24. National Comprehensive Cancer Network: NCCN Clinical Practice Guideline in Oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 13 Sept 2011

  25. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan

    Nozomu Machida, Kouji Yoshizaki, Kentaro Yamazaki, Yusuke Onozawa, Akira Fukutomi, Hirofumi Yasui & Keisei Taku

  2. Division of Medical Oncology, Saint Marianna University Hospital, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, Japan

    Narikazu Boku

Authors
  1. Nozomu Machida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kouji Yoshizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Narikazu Boku
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kentaro Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yusuke Onozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Fukutomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirofumi Yasui
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Keisei Taku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nozomu Machida.

About this article

Cite this article

Machida, N., Yoshizaki, K., Boku, N. et al. Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients. Int J Clin Oncol 18, 279–284 (2013). https://doi.org/10.1007/s10147-012-0374-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-012-0374-z

Keywords

Search

Navigation